Preventative role of interleukin-17 producing regulatory T helper type 17 (Treg17) cells in type 1 diabetes in non-obese diabetic mice

Clinical and Experimental Immunology

Volumn 182, Issue 3, 2015, Pages 261-269

  Bellemore, S M ^a   Nikoopour, E ^a   Schwartz, J A ^a   Krougly, O ^a   Lee Chan, E ^a   Singh, B ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

AhR; IL 22; IL 23; TGF ; Th17 subsets

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CD4 ANTIGEN; CYTOKINE RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL POLARITY; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DIABETOGENESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TH17 CELL; ANIMAL; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PATHOLOGY;

ANIMALS; CELL DIFFERENTIATION; CYTOKINES; DIABETES MELLITUS, TYPE 1; MICE; MICE, INBRED NOD; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84946475476     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12691     Document Type: Article

References (31)

1. Bending D, De La PH, Veldhoen M et al. Highly purified Th17 cells from BDC2.5 NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J Clin Invest 2009; 119:565-72.
2. Martin-Orozco N, Chung Y, Chang SH, Wang YH, Dong C. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur J Immunol 2009; 39:216-24.
3. Nurieva R, Yang XO, Chung Y, Dong C. Cutting edge: in vitro generated Th17 cells maintain their cytokine expression program in normal but not lymphopenic hosts. J. Immunol 2009; 182:2565-8.
4. Ghoreschi K, Laurence A, Yang XP et al. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010; 467:967-71.
5. McGeachy MJ, Bak-Jensen KS, Chen Y et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8:1390-7.
6. Nikoopour E, Schwartz JA, Huszarik K et al. Th17 polarized cells from nonobese diabetic mice following mycobacterial adjuvant immunotherapy delay type 1 diabetes. J Immunol 2010; 184:4779-88.
7. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-40.
8. Morishima N, Mizoguchi I, Takeda K, Mizuguchi J, Yoshimoto T. TGF-beta is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem Biophys Res Commun 2009; 386:105-10.
9. Korn T, Mitsdoerffer M, Croxford AL et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA 2008; 105:18460-5.
10. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-7.
11. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74:1089-100.
12. Stockinger B, Di MP, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol 2014; 32:403-32.
13. Stadinski BD, Delong T, Reisdorph N et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11:225-31.
14. Nikoopour E, Sandrock C, Huszarik K et al. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol 2011; 186:3831-5.
15. Sugita S, Kawazoe Y, Imai A, Yamada Y, Horie S, Mochizuki M. Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet's disease. Arthritis Res Ther 2012; 14:R99.
16. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278:1910-4.
17. Lee Y, Awasthi A, Yosef N et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13:991-9.
18. Rutz S, Eidenschenk C, Ouyang W. IL-22, not simply a Th17 cytokine. Immunol Rev 2013; 252:116-32.
19. Quintana FJ, Basso AS, Iglesias AH et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453:65-71.
20. Quintana FJ, Murugaiyan G, Farez MF et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107:20768-73.
21. Kerkvliet NI, Steppan LB, Vorachek W et al. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes. Immunotherapy 2009; 1:539-47.
22. Di MP, Duarte JH, Ahlfors H et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity 2014; 40:989-1001.
23. Duarte JH, Di MP, Hirota K, Ahlfors H, Stockinger B. Differential influences of the aryl hydrocarbon receptor on Th17 mediated responses in vitro and in vivo. PLOS ONE 2013; 8:e79819.
24. Nikoopour E, Bellemore SM, Singh B. IL-22, cell regeneration and autoimmunity. Cytokine 2015; 74:35-42.
25. Huber S, Gagliani N, Esplugues E et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3 and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 2011; 34:554-65.
26. Oehler L, Foedinger M, Koeller M et al. Interleukin-10 inhibits spontaneous colony-forming unit-granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogenous granulocyte-macrophage colony-stimulating factor release. Blood 1997; 89:1147-53.
27. Singh B, Schwartz JA, Sandrock C, Bellemore SM, Nikoopour E. Modulation of autoimmune diseases by interleukin (IL)-17 producing regulatory T helper (Th17) cells. Ind J Med Res 2013; 138:591-4.
28. Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci USA 2011; 108:11548-53.
29. Esplugues E, Huber S, Gagliani N et al. Control of TH17 cells occurs in the small intestine. Nature 2011; 475:514-8.
30. Nikoopour E, Schwartz JA, Singh B. Therapeutic benefits of regulating inflammation in autoimmunity. Inflamm Allergy Drug Targets 2008; 7:203-10.
31. Gagliani N, Vesely MC, Iseppon A et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature 2015; 523:221-5.